The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global Engineered T Cells market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Engineered T Cells is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Engineered T Cells is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Engineered T Cells in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Engineered T Cells include Autolus Limited, Bellicum Pharmaceuticals, Cells Medica, Elli Lilly and Company, Gilead Sciences, Juno Therapeutics, Novartis, Oxford Biomedica and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Engineered T Cells, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Engineered T Cells.
Report Scope
The Engineered T Cells market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Engineered T Cells market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Engineered T Cells companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Autolus Limited
- Bellicum Pharmaceuticals
- Cells Medica
- Elli Lilly and Company
- Gilead Sciences
- Juno Therapeutics
- Novartis
- Oxford Biomedica
- Pfizer
- Precision Bioscience
- Redmile Group
- Seeking Alpha
- Unum Therapeutics
Segment by Type
- Tumor Infiltrating Lymphocytes
- T Cell Receptor {TCR}
- Chimeric Antigen Receptor(CAR)
Segment by Application
- Hospitals
- Cancer Research Centers
- Clinics
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Engineered T Cells companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Engineered T Cells Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tumor Infiltrating Lymphocytes
1.2.3 T Cell Receptor {TCR}
1.2.4 Chimeric Antigen Receptor(CAR)
1.3 Market by Application
1.3.1 Global Engineered T Cells Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Engineered T Cells Market Perspective (2019-2030)
2.2 Engineered T Cells Growth Trends by Region
2.2.1 Global Engineered T Cells Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Engineered T Cells Historic Market Size by Region (2019-2024)
2.2.3 Engineered T Cells Forecasted Market Size by Region (2025-2030)
2.3 Engineered T Cells Market Dynamics
2.3.1 Engineered T Cells Industry Trends
2.3.2 Engineered T Cells Market Drivers
2.3.3 Engineered T Cells Market Challenges
2.3.4 Engineered T Cells Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Engineered T Cells Players by Revenue
3.1.1 Global Top Engineered T Cells Players by Revenue (2019-2024)
3.1.2 Global Engineered T Cells Revenue Market Share by Players (2019-2024)
3.2 Global Engineered T Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Engineered T Cells Revenue
3.4 Global Engineered T Cells Market Concentration Ratio
3.4.1 Global Engineered T Cells Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Engineered T Cells Revenue in 2023
3.5 Engineered T Cells Key Players Head office and Area Served
3.6 Key Players Engineered T Cells Product Solution and Service
3.7 Date of Enter into Engineered T Cells Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Engineered T Cells Breakdown Data by Type
4.1 Global Engineered T Cells Historic Market Size by Type (2019-2024)
4.2 Global Engineered T Cells Forecasted Market Size by Type (2025-2030)
5 Engineered T Cells Breakdown Data by Application
5.1 Global Engineered T Cells Historic Market Size by Application (2019-2024)
5.2 Global Engineered T Cells Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Engineered T Cells Market Size (2019-2030)
6.2 North America Engineered T Cells Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Engineered T Cells Market Size by Country (2019-2024)
6.4 North America Engineered T Cells Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Engineered T Cells Market Size (2019-2030)
7.2 Europe Engineered T Cells Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Engineered T Cells Market Size by Country (2019-2024)
7.4 Europe Engineered T Cells Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Engineered T Cells Market Size (2019-2030)
8.2 Asia-Pacific Engineered T Cells Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Engineered T Cells Market Size by Region (2019-2024)
8.4 Asia-Pacific Engineered T Cells Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Engineered T Cells Market Size (2019-2030)
9.2 Latin America Engineered T Cells Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Engineered T Cells Market Size by Country (2019-2024)
9.4 Latin America Engineered T Cells Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Engineered T Cells Market Size (2019-2030)
10.2 Middle East & Africa Engineered T Cells Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Engineered T Cells Market Size by Country (2019-2024)
10.4 Middle East & Africa Engineered T Cells Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Autolus Limited
11.1.1 Autolus Limited Company Detail
11.1.2 Autolus Limited Business Overview
11.1.3 Autolus Limited Engineered T Cells Introduction
11.1.4 Autolus Limited Revenue in Engineered T Cells Business (2019-2024)
11.1.5 Autolus Limited Recent Development
11.2 Bellicum Pharmaceuticals
11.2.1 Bellicum Pharmaceuticals Company Detail
11.2.2 Bellicum Pharmaceuticals Business Overview
11.2.3 Bellicum Pharmaceuticals Engineered T Cells Introduction
11.2.4 Bellicum Pharmaceuticals Revenue in Engineered T Cells Business (2019-2024)
11.2.5 Bellicum Pharmaceuticals Recent Development
11.3 Cells Medica
11.3.1 Cells Medica Company Detail
11.3.2 Cells Medica Business Overview
11.3.3 Cells Medica Engineered T Cells Introduction
11.3.4 Cells Medica Revenue in Engineered T Cells Business (2019-2024)
11.3.5 Cells Medica Recent Development
11.4 Elli Lilly and Company
11.4.1 Elli Lilly and Company Company Detail
11.4.2 Elli Lilly and Company Business Overview
11.4.3 Elli Lilly and Company Engineered T Cells Introduction
11.4.4 Elli Lilly and Company Revenue in Engineered T Cells Business (2019-2024)
11.4.5 Elli Lilly and Company Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Detail
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Engineered T Cells Introduction
11.5.4 Gilead Sciences Revenue in Engineered T Cells Business (2019-2024)
11.5.5 Gilead Sciences Recent Development
11.6 Juno Therapeutics
11.6.1 Juno Therapeutics Company Detail
11.6.2 Juno Therapeutics Business Overview
11.6.3 Juno Therapeutics Engineered T Cells Introduction
11.6.4 Juno Therapeutics Revenue in Engineered T Cells Business (2019-2024)
11.6.5 Juno Therapeutics Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Engineered T Cells Introduction
11.7.4 Novartis Revenue in Engineered T Cells Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Oxford Biomedica
11.8.1 Oxford Biomedica Company Detail
11.8.2 Oxford Biomedica Business Overview
11.8.3 Oxford Biomedica Engineered T Cells Introduction
11.8.4 Oxford Biomedica Revenue in Engineered T Cells Business (2019-2024)
11.8.5 Oxford Biomedica Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Engineered T Cells Introduction
11.9.4 Pfizer Revenue in Engineered T Cells Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Precision Bioscience
11.10.1 Precision Bioscience Company Detail
11.10.2 Precision Bioscience Business Overview
11.10.3 Precision Bioscience Engineered T Cells Introduction
11.10.4 Precision Bioscience Revenue in Engineered T Cells Business (2019-2024)
11.10.5 Precision Bioscience Recent Development
11.11 Redmile Group
11.11.1 Redmile Group Company Detail
11.11.2 Redmile Group Business Overview
11.11.3 Redmile Group Engineered T Cells Introduction
11.11.4 Redmile Group Revenue in Engineered T Cells Business (2019-2024)
11.11.5 Redmile Group Recent Development
11.12 Seeking Alpha
11.12.1 Seeking Alpha Company Detail
11.12.2 Seeking Alpha Business Overview
11.12.3 Seeking Alpha Engineered T Cells Introduction
11.12.4 Seeking Alpha Revenue in Engineered T Cells Business (2019-2024)
11.12.5 Seeking Alpha Recent Development
11.13 Unum Therapeutics
11.13.1 Unum Therapeutics Company Detail
11.13.2 Unum Therapeutics Business Overview
11.13.3 Unum Therapeutics Engineered T Cells Introduction
11.13.4 Unum Therapeutics Revenue in Engineered T Cells Business (2019-2024)
11.13.5 Unum Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
